Illuccix clinical trials
Illuccix is named as an intervention in 9 current clinical trials in our USA, China, Canada, Germany, France, Spain, Poland, Czechia, South Korea, Singapore, Italy, UK, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Mexico, Japan, Taiwan, Brazil and Australia registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Novartis Pharmaceuticals (3). The most-studied condition is Prostatic Neoplasm.
Where Illuccix is approved
All regulators →Of the three regulators tracked here, the first to approve Illuccix was the US, on 1 Dec 2020.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Illuccix patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Illuccix, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 3 listed patents; the last listed expires 9 Mar 2036 (US 12109277).
- Latest patent on the drug substance itself: 15 Aug 2028 (US 11369590).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
Patient leaflets for Illuccix
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Illuccix
9 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Illuccix
9 conditionsSponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Illuccix trials
How many clinical trials are testing Illuccix?
9 current trials in our USA, China, Canada, Germany, France, Spain, Poland, Czechia, South Korea, Singapore, Italy, UK, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Mexico, Japan, Taiwan, Brazil and Australia registers name Illuccix (also registered as 68Ga-PSMA-11) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Illuccix trials recruiting patients?
Yes. 2 of the 9 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Illuccix clinical trials?
Novartis Pharmaceuticals (3), First Affiliated Hospital of Fujian Medical University (2), Telix Pharmaceuticals (Innovations) Pty Limited (1) and Peking Union Medical College Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Illuccix works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Illuccix works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Illuccix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.